ndufaf3 Antibody

What is NDUFAF3 and why is it important in mitochondrial research?

NDUFAF3 (NADH dehydrogenase [ubiquinone] 1 alpha subcomplex assembly factor 3) is a critical protein involved in the assembly of mitochondrial complex I (CI). It functions as an assembly factor of the Q-module, physically associating with Q-module subassemblies during complex I biogenesis. Research has shown that NDUFAF3 co-migrates with at least five CI subunits: NDUFS2, NDUFS3, NDUFS7, NDUFS8, and NDUFA5, all part of the Q-module. This interaction suggests NDUFAF3 plays a crucial role in regulating the assembly or ensuring the stability of the Q-module during CI assembly . Mutations in NDUFAF3 have been associated with Leigh Syndrome, a severe mitochondrial disorder, highlighting its clinical significance in understanding mitochondrial dysfunction mechanisms .

What applications are NDUFAF3 antibodies validated for in research settings?

NDUFAF3 antibodies have been validated for multiple research applications, with different products showing specific application profiles. The comprehensive validation data is summarized in the following table:

When selecting an NDUFAF3 antibody for your research, consider the specific application requirements and validated dilution ranges for optimal results .

What are the recommended dilutions and experimental conditions for NDUFAF3 antibody use?

Optimal dilutions and experimental conditions vary depending on the specific NDUFAF3 antibody product and application. Based on manufacturer data, the following recommendations apply:

For PACO59437 (Assay Genie):

• ELISA: 1:2000-1:10000 dilution

• IHC: 1:20-1:200 dilution

  • For paraffin-embedded tissues: dewaxing and hydration followed by antigen retrieval in citrate buffer (pH 6.0)

  • Blocking with 10% normal goat serum for 30 min at room temperature

  • Primary antibody (in 1% BSA) incubated at 4°C overnight

  • Detection using biotinylated secondary antibody and HRP-conjugated SP system

For 25621-1-AP (Proteintech):

• Western Blot: 1:500-1:2000 dilution

• IHC: 1:50-1:500 dilution

  • Suggested antigen retrieval with TE buffer pH 9.0 (alternative: citrate buffer pH 6.0)

• IF/ICC: 1:50-1:500 dilution

Manufacturers emphasize that optimal dilutions may be sample-dependent and should be determined empirically for each experimental system .

What is the reactivity profile and specificity of commercial NDUFAF3 antibodies?

Commercial NDUFAF3 antibodies demonstrate specific reactivity profiles that researchers should consider when designing experiments. Based on validation data:

PACO59437 (Assay Genie):

• Species reactivity: Human

• Host species: Rabbit

• Clonality: Polyclonal

• Immunogen: Recombinant Human NADH dehydrogenase [ubiquinone] 1 α subcomplex assembly factor 3 protein (91-184AA)

25621-1-AP (Proteintech):

• Species reactivity: Human

• Host species: Rabbit

• Clonality: Polyclonal

• Immunogen: NDUFAF3 fusion protein Ag22514

• Positive WB detection in: HEK-293 cells, HeLa cells

• Positive IHC detection in: Human ovary cancer tissue

• Positive IF/ICC detection in: HeLa cells

• Observed molecular weight: 17 kDa (calculated: 20 kDa)

This specificity information helps researchers select the appropriate antibody for their experimental system and interpret results accurately.

What tissues and cell types have been validated for NDUFAF3 antibody use?

NDUFAF3 antibodies have been successfully validated in several human tissues and cell types, providing researchers with reference points for their own experiments:

These validated tissues and cell lines can serve as positive controls when establishing NDUFAF3 detection protocols in new experimental systems .

How can NDUFAF3 antibodies be used to investigate complex I assembly defects in mitochondrial disorders?

NDUFAF3 antibodies offer powerful tools for investigating complex I assembly defects associated with mitochondrial disorders like Leigh Syndrome. Advanced research applications include:

• Characterizing patient samples for NDUFAF3 protein levels and localization to identify potential deficiencies

• Analyzing assembly intermediates in mitochondrial fractions using blue native polyacrylamide gel electrophoresis (BN-PAGE) followed by immunoblotting with NDUFAF3 antibodies

• Tracking the incorporation of NDUFAF3 into assembly intermediates during complex I biogenesis

• Investigating interactions between NDUFAF3 and other assembly factors (particularly NDUFAF4 and TIMMDC1) using co-immunoprecipitation approaches

• Examining the integration of specific subunits (NDUFS3, NDUFV3, and NDUFS5) into their respective modules in disease models

Research has demonstrated that knockdown of NDUFAF3 specifically impairs complex I assembly while leaving other OXPHOS complexes (CII through CV) intact, making NDUFAF3 antibodies valuable for distinguishing between generalized mitochondrial dysfunction and specific complex I assembly defects .

What experimental strategies can be used to study the relationship between NDUFAF3 and NDUFAF4 in complex I biogenesis?

Recent research has revealed complex interactions between NDUFAF3 and NDUFAF4 during complex I biogenesis. To investigate this relationship, researchers can employ several strategies using NDUFAF3 antibodies:

• Co-immunoprecipitation with NDUFAF3 antibodies to detect physical interactions with NDUFAF4 in assembly intermediates

• Comparative analysis of NDUFAF3 and NDUFAF4 incorporation into assembly intermediates using BN-PAGE followed by immunoblotting

• Knockdown/knockout studies of either factor followed by analysis of the other's expression, localization, and function

• Rescue experiments with NDUFAF4 overexpression in NDUFAF3-deficient models

Significantly, research has demonstrated that "forced expression of NDUFAF4 rescues the biogenesis defects in the Q-module and some aspects of the defects in the P-b-module of CI when NDUFAF3 is disrupted" . This finding suggests a potential compensatory relationship that could be further explored using NDUFAF3 antibodies to monitor complex I assembly restoration in rescue experiments.

How can NDUFAF3 antibodies be used to investigate specific module assembly in complex I biogenesis?

NDUFAF3 antibodies provide valuable tools for dissecting the assembly of specific modules in complex I biogenesis. Recent research has revealed that NDUFAF3 influences the assembly of multiple modules, not just the Q-module as previously thought. Advanced experimental approaches include:

• Tracking Q-module assembly: NDUFAF3 co-migrates with Q-module components (NDUFS2, NDUFS3, NDUFS7, NDUFS8, and NDUFA5), allowing researchers to use NDUFAF3 antibodies to monitor Q-module formation

• Analyzing N-module and P-b-module assembly: Research has shown that NDUFAF3 disruption impairs the integration of NDUFS3 into the Q-module, NDUFV3 into the N-module, and NDUFS5 into the P-b-module. NDUFAF3 antibodies can be used to track these integration events

• Investigating assembly intermediate formation: BN-PAGE followed by second-dimension SDS-PAGE and immunoblotting with NDUFAF3 antibodies can reveal assembly intermediates containing NDUFAF3

• Studying TIMMDC1 association: Research has shown that "knockdown of NDUFAF3 or NDUFAF4 reduces the amount of TIMMDC1 associated with assembly intermediates." NDUFAF3 antibodies can help investigate this relationship

These approaches have revealed that NDUFAF3 plays a broader role in complex I assembly than previously recognized, affecting multiple modules simultaneously.

What controls should be included when using NDUFAF3 antibodies in knockdown or knockout models?

When studying NDUFAF3 in genetic knockdown or knockout models, the inclusion of appropriate controls is critical for robust experimental design. Based on research protocols, the following controls are recommended:

• Wild-type controls (e.g., w1118 flies in Drosophila studies or appropriate cell line controls)

• Verification of NDUFAF3 knockdown/knockout efficiency by immunoblotting with NDUFAF3 antibodies

• Multiple independent knockdown/knockout lines using different constructs targeting NDUFAF3 to rule out off-target effects

• Assessment of other OXPHOS complexes (CII-CV) as internal controls using appropriate antibodies

• Functional assays such as in-gel activity assays for CI-CV to correlate protein changes with functional outcomes

Research protocols have successfully employed a combination of silver staining, BN-PAGE, immunoblotting, and in-gel activity assays to comprehensively evaluate NDUFAF3 knockdown effects. In-gel activity assays are particularly valuable, as they revealed reduced CI activity but normal or even increased activity of other complexes in NDUFAF3-knockdown models .

How can NDUFAF3 antibodies be optimized for challenging tissue samples in clinical research?

Optimizing NDUFAF3 antibody protocols for challenging tissue samples in clinical research requires systematic adjustment of several parameters:

• Antigen retrieval method optimization:

  • For 25621-1-AP: Test TE buffer pH 9.0 (primary recommendation) versus citrate buffer pH 6.0 (alternative)

  • For PACO59437: High-pressure antigen retrieval in citrate buffer (pH 6.0) has shown success

• Antibody concentration titration:

  • For PACO59437: Begin with 1:100 dilution (as used in validated protocols) and adjust within the 1:20-1:200 range as needed

  • For 25621-1-AP: Test within the 1:50-1:500 range

• Incubation condition optimization:

  • Extended primary antibody incubation (overnight at 4°C) may improve signal in difficult samples

  • Test different blocking solutions (10% normal goat serum has been successful with PACO59437)

• Detection system selection:

  • For weak signals, consider amplification systems like HRP conjugated SP systems as used successfully with PACO59437

• Comprehensive controls:

  • Include validated positive control tissues (appendix, placenta, or ovary cancer tissue)

  • Include technical negative controls (omitting primary antibody)

  • Compare with other mitochondrial markers in serial sections

These optimization approaches have successfully visualized NDUFAF3 in challenging human tissue samples in clinical research settings .

What are the implications of NDUFAF3-NDUFAF4 interactions for potential therapeutic approaches?

Recent discoveries about NDUFAF3-NDUFAF4 interactions have significant implications for developing therapeutic approaches for mitochondrial disorders:

• Compensatory mechanisms: The finding that "forced expression of NDUFAF4 rescues the biogenesis defects in the Q-module and some aspects of the defects in the P-b-module of CI when NDUFAF3 is disrupted" suggests that NDUFAF4 upregulation could potentially rescue certain NDUFAF3 mutations

• Therapeutic targeting: This compensatory relationship opens up potential gene therapy approaches targeting NDUFAF4 upregulation in patients with specific NDUFAF3 mutations

• Mechanistic insights: Understanding the cooperative mechanisms between NDUFAF3 and NDUFAF4 could lead to the development of small molecules that enhance their interaction or function

• Additional therapeutic targets: The destabilization of TIMMDC1 when either NDUFAF3 or NDUFAF4 is disrupted suggests additional potential therapeutic targets within this pathway

These findings emphasize the importance of precise molecular diagnosis in mitochondrial disorders, as specific mutation characteristics might determine whether compensatory approaches could be effective therapeutic strategies.

How do recent findings about NDUFAF3 challenge previous models of complex I assembly?

Recent research using NDUFAF3 antibodies has challenged previous models of complex I assembly in several important ways:

• Multi-module involvement: While NDUFAF3 was previously thought to primarily affect the Q-module, recent findings demonstrate that it also influences the assembly of N-module and P-b-module, indicating a more extensive role in complex I biogenesis

• Specific subunit integration: Research has revealed that NDUFAF3 facilitates the integration of specific subunits into different modules: NDUFS3 into the Q-module, NDUFV3 into the N-module, and NDUFS5 into the P-b-module

• Cooperative assembly factors: The discovery that NDUFAF4 can rescue NDUFAF3 deficiency for certain aspects of complex I assembly suggests a more complex and potentially redundant relationship between assembly factors than previously understood

• TIMMDC1 connection: The finding that NDUFAF3 disruption destabilizes TIMMDC1 in assembly intermediates reveals previously unknown connections between different assembly factors

These insights, facilitated by NDUFAF3 antibody research, have significantly expanded our understanding of the complex process of mitochondrial complex I assembly and have important implications for understanding mitochondrial disease mechanisms.

What experimental approaches are recommended for investigating NDUFAF3 interactions with other assembly factors?

To investigate NDUFAF3 interactions with other assembly factors, researchers should consider multiple complementary experimental approaches:

• Co-immunoprecipitation studies:

  • Use NDUFAF3 antibodies to pull down protein complexes

  • Analyze co-precipitated proteins by mass spectrometry or immunoblotting for known assembly factors

  • Compare interaction profiles in different cell types or tissues

• Proximity labeling techniques:

  • BioID or APEX2 fusion proteins can identify proteins in close proximity to NDUFAF3

  • These approaches can detect transient or weak interactions often missed by co-immunoprecipitation

• Genetic interaction studies:

  • Test dual knockdown/knockout of NDUFAF3 and other assembly factors

  • Assess synthetic lethality or rescue effects as observed with NDUFAF4

• Live-cell imaging:

  • Fluorescently tagged NDUFAF3 can be used to track dynamic interactions with other factors

  • FRET or BiFC approaches can confirm direct interactions

• Blue native PAGE analysis:

  • Resolve native complexes containing NDUFAF3 and other factors

  • Second-dimension SDS-PAGE followed by immunoblotting can identify components

These approaches have revealed important interactions, such as the compensation between NDUFAF3 and NDUFAF4, and the destabilization of TIMMDC1 when NDUFAF3 is disrupted .

What are the current limitations of NDUFAF3 antibodies in research applications?

While NDUFAF3 antibodies are valuable research tools, current products have several limitations researchers should consider:

• Species reactivity limitations:

  • Currently validated antibodies primarily show reactivity with human samples

  • Limited validation in other model organisms despite conservation of NDUFAF3 across species

• Application constraints:

  • Not all antibodies are validated for all applications (e.g., PACO59437 lacks validation for Western blot)

  • Super-resolution microscopy applications remain largely unexplored

• Isoform specificity:

  • Current antibodies may not distinguish between potential NDUFAF3 isoforms or post-translational modifications

  • This could mask important functional differences in different cellular contexts

• Quantitative limitations:

  • Standardization for quantitative applications remains challenging

  • Absolute quantification of NDUFAF3 levels requires additional controls

• Structural studies:

  • Current antibodies have not been validated for techniques like ChIP-seq or ATAC-seq to study potential nuclear functions

Future development of monoclonal antibodies with broader species reactivity and validation across more diverse applications would significantly enhance the research toolkit for studying NDUFAF3 function.

How might NDUFAF3 antibodies contribute to personalized medicine approaches for mitochondrial disorders?

NDUFAF3 antibodies hold significant potential for advancing personalized medicine approaches for mitochondrial disorders:

• Diagnostic applications:

  • NDUFAF3 antibodies could be used to assess protein expression and localization in patient biopsy samples

  • This could help identify patients with defects in complex I assembly even without genetic mutations in NDUFAF3 itself

• Mutation-specific therapeutic response prediction:

  • The finding that NDUFAF4 overexpression can rescue certain NDUFAF3 deficiency phenotypes suggests that patients with specific NDUFAF3 mutations might benefit from NDUFAF4-targeting approaches

  • NDUFAF3 antibodies could help identify which patients might respond to such therapies

• Treatment monitoring:

  • In therapeutic trials, NDUFAF3 antibodies could monitor restoration of complex I assembly in patient samples

  • This could serve as a biomarker for treatment efficacy

• Tissue-specific effects:

  • Using NDUFAF3 antibodies to compare protein expression and localization across different tissues might explain tissue-specific manifestations of mitochondrial disorders

  • This could inform targeted delivery approaches for therapies

• Biomarker development:

  • Combining NDUFAF3 antibody data with other mitochondrial markers could yield diagnostic or prognostic biomarker panels

  • This could help stratify patients for clinical trials or predict disease progression

These applications highlight how NDUFAF3 antibodies could bridge basic research discoveries to clinical applications in personalized medicine for mitochondrial disorders.